公开(公告)号：WO1996041362A1

公开(公告)日：1996-12-19

申请号：PCT/US1996009906

申请日：1996-06-07

Applicant: ARCH DEVELOPMENT CORPORATION ,  CREWE, Albert, V.

Inventor： ARCH DEVELOPMENT CORPORATION

IPC: H01J37/141

CPC classification number: H01J37/141 ,  H01J2237/1035 ,  H01J2237/142

Abstract: Disclosed are lens apparatus in which a beam of charged particlesis brought to a focus by means of a magnetic field, the lens being situated behind the target position. In illustrative embodiments, a lens apparatus is employed in a scanning electron microscopeas the sole lens for high-resolution focusing of an electron beam, and in particular, an electron beam having an accelerating voltage of from about 10 to about 30,000 V. In one embodiment, the lens apparatus comprises an electrically-conducting coil arranged around the axis of the beam and a magnetic pole piece extending along the axis of the beam at least within the space surrounded by the coil. In other embodiments, the lens apparatus comprises a magnetic dipole or virtual magnetic monopole fabricated from a variety of materials, including permanent magnets, superconducting coils, and magnetizable spheres and needles contained within an energy-conducting coil. Multiple-array lens apparatus are also disclosed for simultaneous and/or consecutive imaging of multiple images on single or multiple specimens. The invention further provides apparatus, methods, and devices useful in focusing charged particle beams for lithographic processes.

Abstract translation: 公开了一种透镜装置，其中带电粒子束通过磁场被聚焦，透镜位于目标位置之后。 在说明性实施例中，在扫描电子显微镜中使用透镜装置用于电子束的高分辨率聚焦的唯一透镜，特别是具有约10至约30,000V的加速电压的电子束。在一个实施例中 透镜装置包括围绕光束的轴线布置的导电线圈和至少在由线圈包围的空间内沿着光束的轴线延伸的磁极片。 在其他实施例中，透镜装置包括由各种材料制成的磁偶极子或虚拟磁单极子，包括永磁体，超导线圈和可磁化球体以及包含在能量传导线圈内的针。 还公开了多阵列透镜装置，用于在单个或多个标本上同时和/或连续成像多个图像。 本发明还提供了用于聚焦用于光刻工艺的带电粒子束的装置，方法和装置。

公开(公告)号：WO1996040397A1

公开(公告)日：1996-12-19

申请号：PCT/US1996009003

申请日：1996-06-06

Applicant: ARCH DEVELOPMENT CORPORATION ,  THE BOARD OF REGENTS FOR NORTHERN ILLINOIS UNIVERSITY

Inventor： ARCH DEVELOPMENT CORPORATION ,  THE BOARD OF REGENTS FOR NORTHERN ILLINOIS UNIVERSITY ,  ROGERS, Robin ,  HORWITZ, E., Philip ,  BOND, Andrew, H.

IPC: B01D15/04

CPC classification number: B01D15/08

Abstract: A solid/liquid phase process for the separation and recovery of an anionic dye from an aqueous solution is disclosed. The solid phase comprises separation particles having surface-bonded poly(ethylene glycol) groups, whereas the aqueous solution from which the anionic dye molecules are separated contains a poly(ethylene glycol) liquid/liquid biphase-forming amount of a dissolved lyotropic salt. After contact between the aqueous solution and separation particles, the anionic dye is bound to the particles. The bound anionic dye molecules are freed from the separation particles by contacting the anionic dye-bound particles with an aqueous solution that does not contain a poly(ethylene glycol) liquid/liquid biphase-forming amount of a dissolved lyotropic salt to form an aqueous anionic dye solution whose anionic dye concentration is preferably higher than that of the initial dye-containing solution.

Abstract translation: 公开了一种用于从水溶液中分离和回收阴离子染料的固相/液相方法。 固相包括具有表面键合的聚（乙二醇）基团的分离颗粒，而分离阴离子染料分子的水溶液含有聚（乙二醇）液/液双相形成量的溶解的致盐盐。 在水溶液和分离颗粒接触之后，阴离子染料与颗粒结合。 通过使阴离子染料结合的颗粒与不含聚（乙二醇）液体/液体双相形成量的溶解的致盐盐的水溶液接触来形成阴离子型阴离子染料分子， 其阴离子染料浓度优选高于初始含染料溶液的染料溶液。

公开(公告)号：WO1996039238A1

公开(公告)日：1996-12-12

申请号：PCT/US1996008355

申请日：1996-06-03

Applicant: ARCH DEVELOPMENT CORPORATION

Inventor： ARCH DEVELOPMENT CORPORATION ,  HORWITZ, E., Philip ,  CHIARIZIA, Renato ,  DIETZ, Mark, L.

IPC: B01D15/08

CPC classification number: B01D15/08 ,  B01D15/36 ,  B01J20/286 ,  B01J20/3092 ,  B01J20/3204 ,  B01J20/321 ,  B01J20/3212 ,  B01J20/3246 ,  B01J2220/54 ,  B01J2220/56 ,  G21F9/06 ,  G21F9/12 ,  G21F9/30

Abstract: An extraction chromatographic material for extracting metal cations from a liquid stream. The extraction chromatographic material is prepared by adsorbing a diesterified methanediphosphonic acid on an inert particulate support.

Abstract translation: 一种用于从液体流中提取金属阳离子的提取色谱材料。 萃取色谱材料通过将二酯化甲基二膦酸吸附在惰性颗粒载体上来制备。

公开(公告)号：WO1996031216A1

公开(公告)日：1996-10-10

申请号：PCT/US1996004681

申请日：1996-04-05

Applicant: ARCH DEVELOPMENT CORPORATION

Inventor： ARCH DEVELOPMENT CORPORATION ,  BRASITUS, Thomas, A. ,  BISSONNETTE, Bruce, Marc ,  SITRIN, Michael, D.

IPC: A61K31/59

CPC classification number: A61K31/593

Abstract: It is provided a method for reducing the incidence of colon cancer by administering a nutrient supplement. The method comprises administering to a subject an effective amount of a non-calcemic analogue of vitamin D3 prior to and subsequent to the initiation of tumorigenesis. The present studies demonstrate that dietary supplementation with one such analogue, 1 alpha ,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, can inhibit the development of colonic tumors in mammals. Moreover, this synthetic analogue of 1 alpha ,25(OH)2D3 appears to be well-tolerated by the animals, and does not induce hypercalcemia or alterations in the serum levels of phosphorus, 25(OH)D3, or 1,25(OH)2D3.

Abstract translation: 提供了通过施用营养补充剂来降低结肠癌发生率的方法。 该方法包括在肿瘤发生开始之前和之后向受试者施用有效量的维生素D3的非钙摄入类似物。 本研究表明，用一种这样的类似物，1α，25-二羟基-16-烯-23-炔-26,27-六氟代胆钙化醇的膳食补充剂可以抑制哺乳动物中结肠肿瘤的发展。 此外，1α，25（OH）2D3的这种合成类似物似乎被动物耐受良好，并且不诱导高血钙或血磷水平25（OH）D3或1,25（OH） ）2D3。

公开(公告)号：WO1996027846A1

公开(公告)日：1996-09-12

申请号：PCT/US1996002439

申请日：1996-03-04

Applicant: ARCH DEVELOPMENT CORPORATION

Inventor： ARCH DEVELOPMENT CORPORATION ,  BICK, Ulrich ,  GIGER, Maryellen, L.

IPC: G06K09/00

CPC classification number: G06K9/482 ,  G06T7/0012 ,  G06T7/11 ,  G06T7/12 ,  G06T7/149 ,  G06T7/155 ,  G06T7/187 ,  G06T2207/20056 ,  G06T2207/20156 ,  G06T2207/30068 ,  G06T2207/30096

Abstract: A method and system for the automated detection of lesions in the medical images. Medical images, such as mammograms are segmented and optionally processing with peripheral enhancement and/or modified median filtering. A modified morphological open operation (104-106) and filtering with a modified mass filter (107-109) are performed for the initial detection of circumscribed lesions. Then, the lesions are matched using a deformable shape template with Fourier descriptors (110-112). Characterization of the match is done using simulated annealing, and measuring the circularity and density characteristics of the suspected lesion. The procedure is performed iteratively at different spatial resolution in which at each resolution step a specific lesion size is detected. The detection of the lesion leads to a localization of a suspicious region and thus the likelyhood of cancer.

Abstract translation: 用于自动检测医学图像中病变的方法和系统。 医疗图像，例如乳房X线照片被分割，并且可选地使用外围增强和/或修改的中值滤波进行处理。 进行修改后的形态开放操作（104-106）和用修改的质量过滤器（107-109）进行过滤，用于初步检测外切损伤。 然后，使用具有傅立叶描述符（110-112）的可变形形状模板来匹配病变。 使用模拟退火进行匹配的表征，并测量疑似病变的圆形度和密度特征。 以不同的空间分辨率迭代地执行该过程，其中在每个分辨率步骤检测到特定的病变大小。 病变的检测导致可疑区域的定位，从而导致癌症的可能性。

公开(公告)号：WO1996004281A1

公开(公告)日：1996-02-15

申请号：PCT/US1995009702

申请日：1995-07-31

Applicant: THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  ARCH DEVELOPMENT CORPORATION ,  THE PENN STATE RESEARCH FOUNDATION, INC. ,  MOSCHEL, Robert, C. ,  PEGG, Anthony, E. ,  DOLAN, M., Eileen ,  CHAE, Mi-Young

Inventor： THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  ARCH DEVELOPMENT CORPORATION ,  THE PENN STATE RESEARCH FOUNDATION, INC.

IPC: C07D473/18

CPC classification number: C07D239/47 ,  C07D239/48 ,  C07D239/50 ,  C07D251/52 ,  C07D473/06 ,  C07D473/18 ,  C07D473/40 ,  C07D487/04 ,  Y10S514/922

Abstract: The present invention provides AGT inactivating compounds such as substituted O -benzylguanines of formula (I) wherein 7- or 9-substituted 8-aza-O -benzylguanines, 7,8-disubstituted O -benzylguanines, 7,9-disubstituted O -benzylguanines, 4(6)-substituted 2-amino-5-nitro-6(4)-benzyloxypyrimidines, and 4(6)-substituted 2-amino-5-nitroso-6(4)-benzyloxypyrimidines, as well as pharmaceutical compositions comprising such compounds along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesion at the O -position of guanine, by administering to a mammal an effective amount of one of the aforesaid compounds, 2,4-diamino-6-benzyloxy-s-triazine, 5-substituted 2,4-diamino-6-benzyloxypyrimidines, or 8-aza-O -benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions of the O -position of guanine.

Abstract translation: 本发明提供AGT灭活化合物，例如式（I）的取代的O 6 - 苄基胍，其中7-或9-取代的8-氮杂-O 6 - 苄基胍，7,8-二取代的O 6 - 苄基胍 7,9-二取代的O 6 - 苄基胍，4（6） - 取代的2-氨基-5-硝基-6（4） - 苄氧基嘧啶和4（6） - 取代的2-氨基-5-亚硝基-6 （4） - 苄氧基嘧啶，以及包含这些化合物以及药学上可接受的载体的药物组合物。 本发明进一步提供了一种增强哺乳动物肿瘤细胞化学治疗的方法，其中抗肿瘤烷化剂通过向哺乳动物施用有效量的一种或多种其中之一，所述抗肿瘤性烷化剂在鸟嘌呤的O 6位上引起细胞毒性损伤 上述化合物，2,4-二氨基-6-苄氧基-s-三嗪，5-取代的2,4-二氨基-6-苄氧基嘧啶或8-氮杂-O 6 - 苄基鸟嘌呤，并向哺乳动物施用有效量 的抗肿瘤性烷化剂，其引起鸟嘌呤的O 6位的细胞毒性损伤。

公开(公告)号：WO1996001127A1

公开(公告)日：1996-01-18

申请号：PCT/US1995008394

申请日：1995-07-05

Applicant: ARCH DEVELOPMENT CORPORATION

Inventor： ARCH DEVELOPMENT CORPORATION ,  RATAIN, Mark, J. ,  GUPTA, Elora

IPC: A61K45/06

CPC classification number: A61K31/47 ,  A61K45/06 ,  Y10S514/01 ,  A61K2300/00

Abstract: This invention provides methods and combination formulations and kits to reduce the toxicity of camptothecin drugs, such as irinotecan (CPT-11). Disclosed are therapeutics and treatment methods employing such drugs in combination with agents that increase conjugative enzyme activity or glucuronosyltransferase activity, and agents that decrease biliary transport protein activity, such as cyclosporine A, the resultant effects of which are to decrease the significant side effects previously associated with treatment using these drugs.

Abstract translation: 本发明提供了减少喜树碱药物如伊立替康（CPT-11）的毒性的方法和组合制剂和试剂盒。 公开了使用这些药物与增加共轭酶活性或葡糖醛酸基转移酶活性的试剂组合的治疗和治疗方法，以及降低胆道转运蛋白活性的试剂，例如环孢菌素A，其结果是减少先前相关的显着副作用 用这些药物治疗。

公开(公告)号：WO1994028027A1

公开(公告)日：1994-12-08

申请号：PCT/US1994006198

申请日：1994-06-01

Applicant: ARCH DEVELOPMENT CORPORATION ,  BLUESTONE, Jeffrey, A. ,  ZIVIN, Robert, A. ,  JOLLIFFE, Linda

Inventor： ARCH DEVELOPMENT CORPORATION

IPC: C07K15/28

CPC classification number: C07K16/2809 ,  A61K38/00 ,  C07K2317/34 ,  C07K2319/02

Abstract: The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. "Humanized" anti-CD3 mAbs, such as gOKT3-5 and gOKT3-7, have been shown to retain, in vitro, all the properties of native OKT3, including T cell activation which has been correlated, in vivo, with the severe side-effects observed in transplant recipients after the first administration of the mAb. Disclosed are modified versions of humanized anti-CD3 mAbs that do not have the property of T cell activation. Further disclosed are methods of using such mAbs.

Abstract translation: 鼠OKT3的结合特异性已经转移到人抗体框架中以降低其免疫原性。 已经表明，“人源化”抗CD3单克隆抗体，如gOKT3-5和gOKT3-7，在体外保留天然OKT3的所有特性，包括体内与体内相关的T细胞活化，严重的一面 - 在首次施用mAb后在移植受体中观察到的影响。 公开了不具有T细胞活化性质的人源化抗CD3 mAb的修饰版本。 还公开了使用这种mAb的方法。

公开(公告)号：WO1994006916A1

公开(公告)日：1994-03-31

申请号：PCT/US1993008432

申请日：1993-09-08

Applicant: ARCH DEVELOPMENT CORPORATION

Inventor： ARCH DEVELOPMENT CORPORATION ,  WEICHSELBAUM, Ralph, R. ,  HALLAHAN, Dennis, E. ,  SUKHATME, Vikas, P. ,  KUFE, Donald, W.

IPC: C12N15/67

CPC classification number: A61K41/0023 ,  A61K38/00 ,  A61K48/00 ,  C07K14/52 ,  C07K14/525 ,  C07K14/82 ,  C07K2319/00 ,  C07K2319/61 ,  C07K2319/71 ,  C07K2319/81 ,  C12N15/63 ,  C12N15/635 ,  C12N15/67 ,  C12N15/85 ,  C12N2830/001 ,  C12N2830/002 ,  C12N2830/008 ,  C12N2830/85 ,  G03G15/2025 ,  G03G2215/2083

Abstract: The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of a transcription factor. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.

Abstract translation: 本发明提供了包含可编码至少一种多肽的编码区可操作地连接的辐射响应增强子 - 启动子的DNA分子。 编码区可以包含多肽的单个编码序列或编码转录因子的DNA结合，激活或抑制结构域的两个或多个编码序列。 还提供了使用这样的DNA分子调节多肽表达和抑制肿瘤生长的方法。

公开(公告)号：WO1993025713A1

公开(公告)日：1993-12-23

申请号：PCT/US1993005857

申请日：1993-06-17

Applicant: ARCH DEVELOPMENT CORPORATION

Inventor： ARCH DEVELOPMENT CORPORATION ,  ROWLEY, Janet, D. ,  DIAZ, Manuel, O.

IPC: C12Q01/68

CPC classification number: C07K14/82 ,  A61K38/00 ,  C12Q1/6886 ,  C12Q2600/112

Abstract: Disclosed is a series of nucleic acid probes for use in diagnosing and monitoring certain types of leukemia using, e.g., Southern and Northern blot analyses and fluorescence in situ hybridization (FISH). These probes detect rearrangements, such as translocations involving chromosome band 11q23 with other chromosomes bands, including 4q21, 6q27, 9p22, 19p13.3, in both dividing leukemic cells and interphase nuclei. The breakpoints in all such translocations are clustered within an 8.3 kb BamHI genomic region of the MLL gene. A novel 0.7 kb BamH1 cDNA fragment derived from this gene detects rearrangements on Southern blot analysis with a single BamHI restriction digest in all patients with the common 11q23 translocations and in patients with other 11q23 anomalies. Northern blot analyses are presented demonstrating that the MLL gene has multiple transcripts and that transcript size differentiates leukemic cells from normal cells. Also disclosed are MLL fusion proteins, MLL protein domains and anit-MLL antibodies.

Abstract translation: 公开了一系列用于诊断和监测某些类型的白血病的核酸探针，其使用例如Southern和Northern印迹分析和荧光原位杂交（FISH）。 这些探针检测重排，例如涉及染色体带11q23与其他染色体带的易位，包括4q21,6q27,9p22,19p13.3在分裂的白血病细胞和间期细胞核中。 所有这些易位中的断点聚集在MLL基因的8.3kb BamHI基因组区域内。 来自该基因的新型0.7kb BamH1 cDNA片段在所有共同11q23易位患者和其他11q23异常患者中，用单次BamHI限制性消化酶检测Southern印迹分析的重排。 提出了Northern印迹分析，证明MLL基因具有多个转录本，转录物大小将白血病细胞与正常细胞分化。 还公开了MLL融合蛋白，MLL蛋白结构域和anit-MLL抗体。